Cytek Biosciences (CTKB) Q2 2026 earnings summary

Executive summary

• Q2 2026 revenue reached $48.1 million, up 6% year-over-year, driven by strong instrument sales and service growth in the U.S. and China.

• New product launches, including the Borealis 60-color cytometer and Aurora Evo automation, reinforced technology leadership and expanded market opportunities.

• Installed base grew to 3,933 instruments, with 142 units added in the quarter.

• Recurring revenue from reagents and services grew 8% year-over-year to $18.5 million, now representing 35% of trailing 12-month revenue.

• Strategic reorganization into customer-aligned business units is underway to enhance market penetration and operational focus.

Financial highlights

• Product revenue was $32.6 million, up 4% year-over-year; service revenue was $15.6 million, up 10%.

• GAAP gross profit was $28.3 million (59% margin), including a one-time $2.8 million tariff refund; excluding the refund, gross margin was 53%.

• Operating expenses rose 15% to $39.7 million, with increases in R&D, sales, marketing, and legal costs.

• GAAP net loss was $12.2 million, compared to $5.6 million in Q2 2025, impacted by higher operating loss, FX losses, and a non-recurring investment write-off.

• Cash, cash equivalents, and marketable securities totaled $262 million at quarter-end.

Outlook and guidance

• Full-year 2026 revenue guidance raised to $207–$212 million, with the midpoint up $1 million.

• Expect higher revenue in Q4 versus Q3, consistent with seasonal patterns.

• Anticipate breakeven Adjusted EBITDA for the full year.

• Recurring revenue from reagents and services expected to increase as the installed base grows.

• No major changes to growth assumptions for instruments, services, and reagents; service revenue expected to continue double-digit growth.